Literature DB >> 25693903

[Cystic fibrosis and associated complications].

C Schwarz1, D Staab.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive inherited metabolic disease. The mutation is located on the long arm of chromosome 7. Due to a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, chloride ion transport is reduced across the cell membrane. As a result, the disease can be described as an exocrinopathy. In all organs with exocrine glands, disorders occur in association with the defective chloride transport. The main impact of this defect is manifested in the lungs. Therefore, the most common cause of death is pulmonary disease with respiratory insufficiency due to recurrent infections. Unfortunately, a cure for the disease is still not available. However, new therapies that may affect the CFTR mutation more specifically give new hope for better therapeutic options in the future. The long-term goal of therapy is to develop a causal therapy for all six different mutation classes and thus for about 2000 mutations.

Entities:  

Mesh:

Year:  2015        PMID: 25693903     DOI: 10.1007/s00108-014-3646-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Authors:  Gregory S Sawicki; James E Signorovitch; Jie Zhang; Dominick Latremouille-Viau; Markus von Wartburg; Eric Q Wu; Lizheng Shi
Journal:  Pediatr Pulmonol       Date:  2011-08-03

2.  [Bronchial and nonbronchial systemic artery embolization in managing haemoptysis: 31 years of experience].

Authors:  G P Cornalba; A Vella; F Barbosa; G Greco; C Michelozzi; A Sacrini; F Melchiorre
Journal:  Radiol Med       Date:  2012-08-09       Impact factor: 3.469

3.  Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.

Authors:  M W Konstan; M Berger
Journal:  Pediatr Pulmonol       Date:  1997-08

4.  Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.

Authors:  M Rosenfeld; R L Gibson; S McNamara; J Emerson; J L Burns; R Castile; P Hiatt; K McCoy; C B Wilson; A Inglis; A Smith; T R Martin; B W Ramsey
Journal:  Pediatr Pulmonol       Date:  2001-11

Review 5.  New clinical diagnostic procedures for cystic fibrosis in Europe.

Authors:  K De Boeck; N Derichs; I Fajac; H R de Jonge; I Bronsveld; I Sermet; F Vermeulen; D N Sheppard; H Cuppens; M Hug; P Melotti; P G Middleton; M Wilschanski
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

Review 6.  Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.

Authors:  David A Stevens; Richard B Moss; Viswanath P Kurup; Alan P Knutsen; Paul Greenberger; Marc A Judson; David W Denning; Reto Crameri; Alan S Brody; Michael Light; Marianne Skov; William Maish; Gianni Mastella
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

7.  Pneumothorax in cystic fibrosis.

Authors:  Patrick A Flume; Charlie Strange; Xiaobu Ye; Myla Ebeling; Thomas Hulsey; Leslie L Clark
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

Review 8.  Cystic fibrosis: genotypic and phenotypic variations.

Authors:  J Zielenski; L C Tsui
Journal:  Annu Rev Genet       Date:  1995       Impact factor: 16.830

9.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

Review 10.  Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.

Authors:  Kalliopi Tanou; Elias Zintzaras; Athanasios G Kaditis
Journal:  Pediatr Pulmonol       Date:  2013-10-25
View more
  3 in total

Review 1.  [Cystic fibrosis : A new disease pattern in adult medicine].

Authors:  D Staab; C Schwarz
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

2.  Novel CFTR Mutations in Two Iranian Families with Severe Cystic Fibrosis.

Authors:  Marzieh Mohseni; Mohammad Razzaghmanesh; Elham Parsi Mehr; Hanieh Zare; Maryam Beheshtian; Hossein Najmabadi
Journal:  Iran Biomed J       Date:  2016-03-27

3.  Identification of a Mutation in the Novel Compound Heterozygous CFTR in a Chinese Family with Cystic Fibrosis.

Authors:  Hongxia Shao; Jingna Hua; Qi Wu; Xiaoge Li; Ming Zhang; Herong Wang; Junping Wu; Long Xu; Yi Xie; Li Li; Huaiyong Chen
Journal:  Can Respir J       Date:  2020-05-07       Impact factor: 2.409

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.